Attached files
file | filename |
---|---|
10-K - 10-K - PLUS THERAPEUTICS, INC. | pstv-10k_20201231.htm |
EX-31.2 - EX-31.2 - PLUS THERAPEUTICS, INC. | pstv-ex312_7.htm |
EX-31.1 - EX-31.1 - PLUS THERAPEUTICS, INC. | pstv-ex311_9.htm |
EX-23.1 - EX-23.1 - PLUS THERAPEUTICS, INC. | pstv-ex231_8.htm |
EX-10.24 - EX-10.24 - PLUS THERAPEUTICS, INC. | pstv-ex1024_87.htm |
EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Plus Therapeutics, Inc. for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on February 22, 2021, (the “Report”), Marc H. Hedrick, as President & Chief Executive Officer of Plus Therapeutics, Inc., and Andrew Sims, as Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that:
1. |
The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934. |
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Plus Therapeutics, Inc. |
|
|
By: |
|
/s/ Marc H. Hedrick, MD |
Dated: February 22, 2021 |
|
|
|
Marc H. Hedrick, MD |
|
|
|
|
President & Chief Executive Officer |
|
|
|
|
|
|
|
By: |
|
/s/ Andrew Sims |
Dated: February 22, 2021 |
|
|
|
Andrew Sims |
|
|
|
|
Chief Financial Officer |